

- 10) Provisor AJE, *et al*: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. *J Clin Oncol* 15: 76-84, 1997.
- 11) Meyers PA: Randomized study of incorporating IFF into neoadjuvant and adjuvant osteogenic sarcoma. Childrens Cancer Group Study CCG-7921, 1993. Scandinavia
- 12) Saeter G, *et al*: Treatment of osteosarcoma of the extremities with the T-10 protocol with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. *J Clin Oncol* 9: 1766-1775, 1991.
- 13) Saeter G, *et al*: Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. *Cancer* 75: 1084-1093, 1995. Japan
- 14) Tsuchiya H, *et al*: Prognosis of osteosarcoma treated by limb-salvage surgery: the ten-year intergroup study in Japan. *Jpn J Clin Oncol* 22(5): 347-353, 1992.
- 15) 井須和男・他: 骨肉腫に対する Adjuvant Chemotherapy における多施設共同研究の経験と将来への展望. 日整会誌 70(6): S 999, 1996. Single institute
- 16) Rosen G, *et al*: Preoperative chemotherapy for osteogenic sarcoma: selection of post operative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. *Cancer* 49: 1221-1230, 1982.
- 17) Meyers PA, *et al*: Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. *J Clin Oncol* 10(1): 5-15, 1992.
- 18) Meyers PA, *et al*: Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering. *Cancer Treat Res* 62: 309-322, 1993.
- 19) Meyers PA, *et al*: Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T 12) protocol. *J Clin Oncol* 16(7): 2452-2458, 1998.
- 20) Ferrari S, *et al*: Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. *Ann Oncol* 8: 765-771, 1997.
- 21) Bacci G, *et al*: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. *Cancer* 72: 3227-3238, 1993.
- 22) Meyer WM, *et al*: Osteosarcomas. Clinical features and evolving surgical and chemotherapeutic strategies. *Pediatr Clin North Am* 38: 317-348, 1991
- 23) Wada T, *et al*: A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: Preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor oncology 53: 221-227, 1996.
- 24) 石井 猛・他: 当院における骨肉腫化学療法の変遷と治療成績の検討. 日整会誌 70(6): S 995, 1996.
- 25) 井須和男・他: 骨肉腫補助化学療法における多剤併用療法の役割. 整外災外 43: 1067-1073, 2000.
- 26) Uchida A, *et al*: Neoadjuvant for pediatric osteosarcoma patients. *Cancer* 79: 411-415, 1997.
- 27) Miser J, *et al*: Treatment of high-grade osteosarcoma with ifosfamide, mesna, adriamycin, high dose methotrexate with or without cisplatin, abstracted. *Proc Annu Meet Am Soc Clin Oncol* 11: A 1262, 1992.
- 28) Meyer WH, *et al*: Curative therapy for osteosarcoma without cisplatin-preliminary results of SJCRH OS-91. *Proc ASCO* 16: 1844, 1997.
- 29) Goorin AM, *et al*: Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/The Children's Hospital study III. *J Clin Oncol* 5: 1178-1184, 1987.
- 30) Weiner M, *et al*: Neoadjuvant high dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. *Cancer Treat Rep* 70: 1431-1432, 1986.
- 31) Ettinger LJ, *et al*: Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity. *J Clin Oncol* 4: 353-362, 1986.
- 32) Miser JS, *et al*: Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. *J Clin Oncol* 5: 1191-1198, 1987.
- 33) Delpine N, *et al*: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. *Cancer*

- 78: 2127-2135, 1996.  
Randomized study
- 34) Link MP, *et al*: Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Update results of the Multi-Institutional Osteosarcoma Study. *Clin Orthop Relate Res* 270: 8-14, 1991.
- 35) Link MP, *et al*: The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 314: 1600-1606, 1986.
- 36) Eilber FP, *et al*: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. *J Clin Oncol* 5: 21-26, 1987.
- 37) Edmonson JH, *et al*: A controlled pilot study of high dose methotrexate as post-surgical adjuvant treatment for primary osteosarcoma. *J Clin Oncol* 2: 152-156, 1984.  
Metaanalysis
- 38) Graf N, *et al*: Methotrexate pharmacokinetics and prognosis in osteosarcoma. *J Clin Oncol* 12: 1443-1451, 1994.
- 39) Smith MA, *et al*: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma. *J Natl Cancer Inst* 83: 1460-1470, 1991.
- 40) Grem JL, *et al*: The role of methotrexate in osteosarcoma. *J Natl Cancer Inst* 80: 626-656, 1988.
- 41) Smith MA, *et al*: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma. *J Natl Cancer Inst* 83: 1460-1470, 1991.  
Arterial infusion
- 42) Hudson M, *et al*: Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10-year experience. *J Clin Oncol* 8: 1988-1997, 1996.
- 43) 土屋弘行・他: 四肢悪性骨・軟部腫瘍に対するカプエイン併用動注化学療法. *癌の臨床* 41(41): 1156-1164, 1995.
- 44) Tsuchiya H, *et al*: Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. *Anticancer Res* 18: 657-666, 1998.  
Lung metastasis
- 45) Ward WG, *et al*: Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. *J Clin Oncol* 12: 1849-1858, 1994.
- 46) Winkler K, *et al*: Die Chemotherapie des Osteosarkoms. *Z Orthop* 130: 285-289, 1992.
- 47) Bacci G, *et al*: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation: Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. *Cancer* 79: 245-254, 1997.
- 48) Picci P, *et al*: Salvage treatment with high-dose ifosfamide and surgery for osteosarcoma patients relapsed with lung metastases. Preliminary results. *Proc ASCO* 15: 459 (Abstr 1438), 1996.  
MFH of bone
- 49) Bramwell VHC, *et al*: Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. *J Clin Oncol* 17: 3260-3269, 1999.
- 50) Bacci G, *et al*: Neoadjuvant chemotherapy in malignant fibrous histiocytoma and in osteosarcoma located in the extremity: Analogies and differences between the two tumors. *Ann Oncol* 8: 1107-1115, 1997.  
Ewing's family sarcoma  
EICSSS
- 51) Paulussen M, *et al*: [EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study)-preliminary results]. *Klin Padiatr* 211(4): 276-283, 1999.
- 52) Paulussen M, *et al*: Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. *J Clin Oncol* 19(6): 1818-1829, 2001.
- 53) Dunst J, *et al*: Radiation therapy as local treatment in Ewing's sarcoma: Results of the cooperative Ewing's sarcoma studies CESS 81 and CESS 86. *Cancer* 67: 2818-2825, 1991.
- 54) Jurgen H, *et al*: Die cooperative Ewing-Sarkom Studie CESS 81 der GPO-Analyse nach 4 Jahren. *Klin Padiatr* 197: 225-232, 1985.
- 55) Cotterill SJ, *et al*: Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. *J Clin Oncol* 18(17): 3108-3114, 2000.
- 56) Hense HW, *et al*: Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI) CESS studies. *Ann Oncol* 10(9): 1073-1077, 1999.
- 57) Ahrens S, *et al*: Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. *Med Pediatr Oncol* 32(3): 186-195, 1999.
- 58) Paulussen M, *et al*: Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. *J Clin*

- Oncol* 16(9): 3044-3052, 1998.
- 59) Paulussen M, *et al*: Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. *Ann Oncol* 9(3): 275-281, 1998.
  - 60) Hoffmann C, *et al*: Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. *Cancer* 85(4): 869-877, 1999.  
Intergroup study (CCG, POG)
  - 61) Maygarden SJ, *et al*: Ewing sarcoma of bone in infants and toddlers. A clinicopathologic report from the Intergroup Ewing's Study. *Cancer* 71(6): 2109-2118, 1993.
  - 62) Evans RG, *et al*: Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. *J Clin Oncol* 9(7): 1173-1180, 1991.
  - 63) Burgert EO, *et al*: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. *J Clin Oncol* 8(9): 1514-1524, 1990.
  - 64) Nesbit ME, *et al*: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. *J Clin Oncol* 8(10): 1664-1674, 1990.
  - 65) Evans R, *et al*: Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. *Int J Radiat Oncol Biol Phys* 11(1): 129-136, 1985.
  - 66) Evans RG, *et al*: Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. *J Clin Oncol* 9(7): 1173-1180, 1991.
  - 67) Burgert EO, *et al*: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. *J Clin Oncol* 8(9): 1514-1524, 1990.
  - 68) Siegal GP, *et al*: Primary Ewing's sarcoma involving the bones of the head and neck. *Cancer* 60(11): 2829-2840, 1987.
  - 69) Shirley SK, *et al*: Ewing's sarcoma in bones of the hands and feet: a clinicopathologic study and review of the literature. *J Clin Oncol* 3(5): 686-697, 1985.
  - 70) Evans R, *et al*: Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones. *Int J Radiat Oncol Biol Phys* 11(1): 129-136, 1985.
  - 71) Thomas PR, *et al*: Primary Ewing's sarcoma of the ribs. A report from the intergroup Ewing's sarcoma study. *Cancer* 51(6): 1021-1027, 1983.
  - 72) Cangir A, *et al*: Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. *Cancer* 66(5): 887-893, 1990.  
Italia
  - 73) Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. *Cancer* 86(3): 421-428, 1999.  
Scandinavea
  - 74) Saeter G, *et al*: Chemotherapy for osteosarcoma and Ewing's sarcoma. *Acta Orthop Scand Suppl* 273: 120-125, 1997.  
SFOP (France)
  - 75) Oberlin O, *et al*: Ewing's sarcoma: towards a common protocol for adults and children. *Cancer Radiother* 4(Suppl 1): 141 s-144 s, 2000.
  - 76) Carrie C, *et al*: Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology. *Med Pediatr Oncol* 33(5): 444-449, 1999.
  - 77) Oberlin O, *et al*: No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. *J Clin Oncol* 10(9): 1407-1412, 1992.
  - 78) Demeocq F, *et al*: Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP). *Cancer Chemother Pharmacol* 24(Suppl 1): S 45-47, 1989.  
Single institute studies
  - 79) Bacci G, *et al*: Non-metastatic Ewing's sarcoma: results in 98 patients treated with neoadjuvant chemotherapy. *Ital J Orthop Traumatol* 17(4): 449-465, 1991.
  - 80) Bacci G, *et al*: Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. *Cancer* 63: 1477-1486, 1989.
  - 81) Bacci G, *et al*: Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase—results of two sequential studies. *Can-*

- cer 82(6):1174-1183, 1998.
- 82) Bacci G, *et al*: No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies. *J Chemother* 5(4):247-257, 1993.
  - 83) Bacci G, *et al*: Prognostic factors in non-metastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. *J Clin Oncol* 18(1):4-11, 2000.
  - 84) Bacci G, *et al*: Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma. *Acta Oncol* 37(7-8):671-676, 1998.
  - 85) Picci P, *et al*: Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. *J Clin Oncol* 15(4):1553-1559, 1997.
  - 86) Picci P, *et al*: Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. *J Clin Oncol* 11(9):1763-1769, 1993.
  - 87) Bacci G, *et al*: Metachronous pulmonary metastases resection in patients with Ewing's sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. *Eur J Cancer* 31 A(6):999-1001, 1995.
  - 88) Bacci G, *et al*: Ewing's sarcoma of the bone. Anatomoclinical study of 424 cases. *Minerva Pediatr* 44(7-8):345-359, 1992.
  - 89) Kinsella T, *et al*: Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. *Int J Radiat Oncol Biol Phys* 20:389-395, 1991.
  - 90) Miser JS, *et al*: Treatment of peripheral neuroepithelioma in children and young adults. *J Clin Oncol* 5:1752-1758, 1987.
  - 91) Meyer WH, *et al*: Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. *J Clin Oncol* 10(11):1737-1742, 1992.
  - 92) Wexler LH, *et al*: Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. *Cancer* 78:901-911, 1996.
  - 93) Hayes FA, *et al*: The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy. *J Clin Oncol* 1(1):1983.
  - 94) Zucker JM, *et al*: Intensive systemic chemotherapy in localized Ewing's sarcoma in childhood. A historical trials. *Cancer* 52:415-423, 1983.
  - 95) Oberlin O, *et al*: The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. *Eur J Cancer Clin Oncol* 21:463-467, 1985.
  - 96) Delpine N, *et al*: Is age a prognostic in localised Ewing's sarcoma treated by multi-drug regimens and systematic surgery? *Proc ASCO* 16:525 a, 1997.
  - 97) Wunder JS, *et al*: The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. *J Bone Joint Surg Am* 80(7):1020-1033, 1988.
  - 98) Terek RM, *et al*: Treatment of femoral Ewing's sarcoma. *Cancer* 78(1):70-78, 1996.
  - 99) Kushner BH, *et al*: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. *J Clin Oncol* 13(11):2796-2804, 1995.
  - 100) Rosen G, *et al*: Ewing's sarcoma. Ten year experience with adjuvant chemotherapy. *Cancer* 47:2204-2213, 1981.
  - 101) Kushner BH, *et al*: Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. *Med Pediatr Oncol* 35(5):468-474, 2000.
  - 102) Young MM, *et al*: Treatment of sarcomas of the chest wall using intensive combined modality therapy. *Int J Radiat Oncol Biol Phys* 16(1):49-57, 1989.
  - 103) Stea B, *et al*: Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy. *Int J Radiat Oncol Biol Phys* 13(12):1797-1805, 1987.
  - 104) Miser JS, *et al*: Treatment of peripheral neuroepithelioma in children and young adults. *J Clin Oncol* 5(11):1752-1758, 1987.
  - 105) Terrier P, *et al*: Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? *Eur J Cancer* 31 A(3):307-314, 1995.
  - 106) Hartman KR, *et al*: Prognostic value of histopathology in Ewing's sarcoma. Long-term follow-up of distal extremity primary tumors. *Cancer* 67(1):163-171, 1991.
  - 107) Womer RB, *et al*: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. *Eur J Cancer* 36(1):87-94, 2000.
  - 108) Miser JS, *et al*: Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas

- and other tumors of children and young adults. *J Clin Oncol* 8: 1191-1198, 1987.
- 109) Kushner BH, *et al*: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. *J Clin Oncol* 13(11): 2796-2804, 1995.
- 110) Evans RG, *et al*: Sequential half-body irradiation (SHIB) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma—A pilot study. *Radiat Oncol Biol Phys* 10: 2363-2368, 1984.  
骨髓移植併用
- 111) Kushner BH, *et al*: How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. *J Clin Oncol* 19(3): 870-880, 2001.
- 112) Burdach S, *et al*: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. *Ann Oncol* 11(11): 1451-1462, 2000.
- 113) Graham ML, *et al*: Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophamide followed by autologous bone marrow rescue. *J Clin Oncol* 10(12): 1857-1864, 1992.
- 114) Burdach H, *et al*: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. *J Clin Oncol* 11: 1482-1488, 1993.  
成人発生の悪性軟部腫瘍進行例の化学療法
- 115) Gottlieb JA, *et al*: Chemotherapy of sarcomas with a combination of Adriamycin and diethyl triazeno imidazole-carboxamine. *Cancer* 30: 1632-1638, 1972.
- 116) Borden EC, *et al*: Randomized comparison of three adriamycin regimens for treatment of metastatic soft tissue sarcomas. *J Clin Oncol* 5: 840-850, 1987.
- 117) Omura GA, *et al*: A randomized study of adriamycin with and without dimethyletriazolo imidazole carboxamine in advanced uterine sarcomas. *Cancer* 52: 626-632, 1983.
- 118) Pinedo HM, *et al*: Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules. *Cancer* 53: 1825-1832, 1984.
- 119) Schoenfeld DA, *et al*: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide versus vincristine actinomycin-D and cyclophosphamide for advanced sarcoma. *Cancer* 50: 2757-2762, 1982.
- 120) Baker L, *et al*: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide and actinomycin D for advanced soft tissue sarcoma: A randomized comparative trial. *J Clin Oncol* 5: 851-857, 1987.
- 121) Bramwell V, *et al*: Cyclophosphamide vs ifosfamide and mesna: Final report of a randomized phase II trial in adult soft tissue sarcoma. *Eur J Cancer Clin Oncol* 7: 126-131, 1989.
- 122) Bramwell VH, *et al*: Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. *Cancer Chemother Pharmacol* 31(Suppl 2): S 180-184, 1993.
- 123) Antman K, *et al*: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma. *J Clin Oncol* 11: 1276-1285, 1993.
- 124) Santoro A, *et al*: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 13(7): 1537-1545, 1995.
- 125) Edmonson JH, *et al*: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. *J Clin Oncol* 11(7): 1269-1275, 1993.
- 126) Blum RH, *et al*: Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. *Cancer Chemother Pharmacol* 31(Suppl 2): S 238-240, 1993.
- 127) Palumbo R, *et al*: Dose-intensive first line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. *Eur J Cancer* 35(1): 66-72, 1999.
- 128) Toma S, *et al*: Doxorubicin plus epidoxorubicin at escalating doses in the treatment of locally advanced and/or metastatic sar

- comas. *Cancer Chemother Pharmacol* 31(Suppl 2): S 222-227, 1993.
- 129) Merimsky O, *et al*: Adriamycin-ifosfamide induction chemotherapy for extremity soft tissue sarcoma: comparison of two non-randomized protocols. *Oncol Rep* 6(4): 913-920, 1999.
- 130) Sutton G, *et al*: Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 62(2): 226-229, 1996.
- 131) Nielsen OS, *et al*: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer* 36(1): 61-67, 2000.
- 132) Van Glabbeke M, *et al*: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 17(1): 150-157, 1999.
- 133) Chevreau C, *et al*: Phase I - II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). *Am J Clin Oncol* 22(3): 267-272, 1999.
- 134) Barista I, *et al*: Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. *J Surg Oncol* 73(1): 12-16, 2000.
- 135) Frustaci S, *et al*: Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. *Tumori* 85(4): 229-233, 1999.
- 136) Rosen G, *et al*: Synovial sarcoma; Uniform response of metastases to high dose ifosfamide. *Cancer* 73: 2506-2511, 1994.
- 137) Le Cesne A, *et al*: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. *J Clin Oncol* 18(14): 2676-2684, 2000.
- 138) Steward WP, *et al*: The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. *Cancer Chemother Pharmacol* 31(suppl 2): S 241-244, 1993.
- 139) Nielsen OS, *et al*: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. *Br J Cancer* 78(12): 1634-1639, 1998.
- 140) Fernberg JO, *et al*: Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. *Acta Orthop Scand Suppl* 285: 62-68, 1999.
- 141) Comandone A, *et al*: Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas. *Anticancer Res* 20(3 B): 2077-2080, 2000.
- 142) Budd GT, *et al*: Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: A Southwest Oncology Group study. *Cancer Chemother Pharmacol* 31(Suppl 2): S 213-216, 1993.
- 143) Verweij J, *et al*: Randomized phase II study of docetaxel versus doxorubicin in first and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. *J Clin Oncol* 18(10): 2081-2086, 2000.
- 144) Verweij J: Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. *Anticancer Drugs* 6(Suppl 4): 19-24, 1995.
- 145) van Hoesel QG, *et al*: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. *Ann Oncol* 5(6): 539-542, 1994.
- 146) Edmonson JH, *et al*: Phase II study of docetaxel in advanced soft tissue sarcomas. *Am J Clin Oncol* 19(6): 574-576, 1996.
- 147) Sutton G, *et al*: Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. *Gynecol Oncol* 74(3): 346-349, 1999.
- 148) Barcerzak SP, *et al*: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. *Cancer* 76: 2248-2252, 1995.
- 補助化学療法
- 149) Antman K, *et al*: Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10

- year results and review of literature. In *Adjuvant Therapy of Cancer VI* (edited by Salmon SE), PA, WB Saunders, Philadelphia, 1990, pp 529-543.
- 150) Alvegard TA, *et al*: Adjuvant chemotherapy with doxorubicin in high grade soft tissue sarcoma: A randomized trial of the Scandinavian Sarcoma Group. *J Clin Oncol* 7: 1504-1513, 1989.
  - 151) Rosenberg SA, *et al*: Adjuvant chemotherapy for treatment of extremity soft tissue sarcoma: review of National Cancer Institute experience. *Cancer Treat Symposia* 3: 83, 1985.
  - 152) Chang AE, *et al*: Adjuvant chemotherapy for patients with highgrade soft tissue sarcomas of the extremity. *J Clin Oncol* 6: 1491, 1988.
  - 153) Cregan ET, *et al*: A Clinical trial adriamycin (NSG 123127) in advanced sarcomas (Abstract). *Oncology* 34-90, 1977.
  - 154) Schoenfield DA, *et al*: A comparison of adriamycin versus vincristine and adriamycin versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. *Cancer* 50: 2757, 1982.
  - 155) Borden EC, *et al*: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. *J Clin Oncol* 5: 840, 1987.
  - 156) Borden EC, *et al*: Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. *Cancer* 66: 862, 1990.
  - 157) Benjamin RS, *et al*: The importance of combination chemotherapy for adjuvant treatment of high risk patients with soft tissue sarcomas of the extremities. In *Adjuvant Therapy of Cancer V* (edited by Salmon SE), Grune & Stratton, New York, 1987, pp 735-744.
  - 158) Edmonson JH, *et al*: A randomized study of systemic chemotherapy following complete excision of nonosseous sarcoma. *J Clin Oncol* 2: 1390-1396, 1984.
  - 159) Baker AR, *et al*: National Cancer Institute experience in the management of high grade extremity soft tissue sarcoma. In *Recent concepts in Sarcoma Treatment* (ed by Ryan JR, Baker LO), Kluwer Academic, Dordrecht, the Netherlands, 1988, pp 123-129.
  - 160) Bui NB, *et al*: First results of a prospective randomized study of CYVADIC adjuvant chemotherapy in adults with operable high risk soft tissue sarcoma. *Proc ASCO* 8: 318, 1989.
  - 161) Ravaud A, *et al*: Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma: A randomized prospective trial. In *Adjuvant Therapy of Cancer VI* (edited by Salmon SE), Grune & Stratton, New York, 1990, pp 556-566.
  - 162) Bramwell BV, *et al*: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-Reduced local recurrence but no improvement in survival; A study of the European Organization for Research and Treatment of cancer soft tissue and bone sarcoma group. *J Clin Oncol* 12: 1137-1149, 1994.
  - 163) Gherlizoni F, *et al*: Soft tissue sarcomas: The experience at the Istituto Ortopedico Rizzoli. *Chir Organi Mov* 75: 150-154, 1990.
  - 164) Picci P, *et al*: Results of a randomized trial for a treatment of localized soft tissue tumors of the extremities in adult patients. In *Recent concepts in Sarcoma Treatment* (ed by Ryan JR, Baker LO), Kluwer Academic, Dordrecht, the Netherlands, 1988, pp 144-155.
  - 165) Sarcoma meta-analysis collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. *Lancet* 350: 1647-1654, 1997.
- Neoadjuvant and Radiochemotherapy
- 166) Eileber FR, *et al*: Intraarterial adriamycin, radiation therapy, and surgical excision for extremity skeletal and soft tissue sarcomas. *Dev Oncol* 26: 141-152, 1984.
  - 167) Eilber FR, *et al*: A randomized prospective trial using post-chemotherapy (Adriamycin) in high grade extremity soft-tissue sarcoma. *Am J Clin Oncol* 11: 39-45, 1988.
  - 168) Hoekstra HJ, *et al*: A combination of intraarterial chemotherapy, preoperative and post operative radiotherapy, and surgery as limb saving treatment of primarily unresectable high-grade soft tissue sarcomas of the extremities. *Cancer* 63: 59-62, 1989.
  - 169) Gherlinzoni F, *et al*: A randomized trial for the treatment of high grade soft tissue sarcomas of the extremities: Preliminary observations. *J Clin Oncol* 4: 552-558, 1986.
  - 170) Wilson RE, *et al*: Doxorubicin chemotherapy in the treatment of soft tissue sarcoma: Combined results of two randomized trials. *Arch Surg* 121: 1354-1359, 1986.
  - 171) Denton JW, *et al*: Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. *Surg Gynecol Obstet* 158: 545-551, 1984.
  - 172) Meric F, *et al*: Impact of neoadjuvant chemo-

therapy on postoperative morbidity in soft  
tissue sarcomas. *J Clin Oncol* 18(19):3378-

383, 2000.

---